CN111068043A - Composition rich in chicory and inulin, preparation method thereof and preparation for preventing gout - Google Patents
Composition rich in chicory and inulin, preparation method thereof and preparation for preventing gout Download PDFInfo
- Publication number
- CN111068043A CN111068043A CN201911338991.3A CN201911338991A CN111068043A CN 111068043 A CN111068043 A CN 111068043A CN 201911338991 A CN201911338991 A CN 201911338991A CN 111068043 A CN111068043 A CN 111068043A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- chicory inulin
- rhizome
- chicory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000007542 Cichorium intybus Nutrition 0.000 title claims abstract description 48
- 229920001202 Inulin Polymers 0.000 title claims abstract description 41
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 title claims abstract description 41
- 229940029339 inulin Drugs 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 201000005569 Gout Diseases 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 241000723343 Cichorium Species 0.000 title claims description 46
- 239000000284 extract Substances 0.000 claims abstract description 137
- 238000002156 mixing Methods 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 11
- 241000132012 Atractylodes Species 0.000 claims abstract description 11
- 241000218158 Clematis Species 0.000 claims abstract description 11
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 11
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 11
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 11
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 241000748223 Alisma Species 0.000 claims abstract description 10
- 235000003826 Artemisia Nutrition 0.000 claims abstract description 10
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 10
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 10
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 10
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 10
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 10
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 10
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 10
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 10
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 10
- 240000009022 Smilax rotundifolia Species 0.000 claims abstract description 10
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims abstract description 10
- 244000030166 artemisia Species 0.000 claims abstract description 10
- 235000009052 artemisia Nutrition 0.000 claims abstract description 10
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 241000219784 Sophora Species 0.000 claims abstract description 5
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 4
- 238000010438 heat treatment Methods 0.000 claims description 30
- 238000010992 reflux Methods 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 241000246044 Sophora flavescens Species 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 240000007890 Leonurus cardiaca Species 0.000 claims 3
- 238000000227 grinding Methods 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 13
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 12
- 229940116269 uric acid Drugs 0.000 abstract description 12
- 208000002193 Pain Diseases 0.000 abstract description 8
- 210000001503 joint Anatomy 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 210000000988 bone and bone Anatomy 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 210000001835 viscera Anatomy 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 244000298479 Cichorium intybus Species 0.000 abstract 2
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 241000207925 Leonurus Species 0.000 description 6
- 241001106477 Paeoniaceae Species 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000766380 Iphigenia Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0051—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Fructofuranans, e.g. beta-2,6-D-fructofuranan, i.e. levan; Derivatives thereof
- C08B37/0054—Inulin, i.e. beta-2,1-D-fructofuranan; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Sustainable Development (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition rich in chicory inulin, a preparation method thereof and a preparation for preventing gout. The feed comprises the following raw materials in parts by weight: 40-100 parts of chicory inulin, 10-30 parts of extracts of the cang and the white atractylodes rhizome respectively, 10-30 parts of an artemisia leaf extract, 30-60 parts of a fried coix seed extract, 5-15 parts of an amur corktree bark extract, 20-40 parts of a glabrous greenbrier rhizome extract, 20-40 parts of a clematis root extract, 20-40 parts of a plantain herb extract, 20-40 parts of a giant knotweed rhizome extract, 10-20 parts of an alisma rhizome extract, 10-20 parts of a motherwort herb extract, 10-20 parts of a red paeony root extract, 10-20 parts of earthworm protein powder, 10-20 parts of peach kernel powder, 10-20 parts of a lightyellow sophora root extract, 8-15 parts of a cortex lycii radicis extract, 3-8 parts of. The composition of the invention can reduce the internal uric acid, restore the normal function of viscera and relieve the pain of muscles, bones and joints. And the preparation method can be realized only by uniformly mixing all the raw materials, is simple and easy to control in operation, and is beneficial to large-scale production.
Description
Technical Field
The invention belongs to the technical field of natural active substance extraction, and particularly relates to a composition rich in chicory inulin, a preparation method and a preparation for preventing gout.
Background
Gout (gout) is a heterogeneous group of metabolic diseases that develop as a result of long-term hyperuricemia (hyperuricemia) resulting in the deposition of urate in joints and soft tissues. Because missense mutations (missense mutations) in the uricase gene, humans and apes lack uricase that is commonly present in other mammals, and cannot break down uric acid into allantoin (allintoin) that is more water-soluble and easier to excrete, while the kidneys have a stronger uric acid reabsorption capacity, with the result that the blood uric acid level is higher than that of other mammals, and gout is therefore a metabolic disease specific to humans and apes. The clinical manifestations of gout are recurrent acute arthritis, tophus deposition, gouty chronic arthritis and joint deformity, often involving the kidney, causing chronic interstitial nephritis, kidney stone, etc. Gout is classified into primary gout and secondary gout. Primary gout is caused by congenital purine metabolic defect, and is often accompanied by obesity, hypertension, hyperlipidemia and the like. Secondary gout can be caused by various factors, such as lead poisoning, renal dysfunction and the use of certain drugs, wherein the use of diuretics is an important factor causing secondary gout. The existing medicines are still not comprehensive enough to prevent gout and cannot give consideration to comprehensive conditioning.
Chicory has the functions of regulating blood fat and reducing uric acid, has good regulating effect on hyperuricemia, and can obviously improve hyperuricemia and abdominal obesity caused by high purine diet. The action mechanism of the compound can reduce the activity of liver acetyl coenzyme A carboxylase, fatty acid synthetase and xanthine oxidase, thereby playing a role in comprehensively regulating uric acid and abdominal fat accumulation. The chicory is a plant used as both medicine and food, the leaf can be used for preparing lettuce, the root contains inulin and aromatic substances, the substitute coffee can be extracted, the activity of human digestive organs is promoted, and the chicory has the effects of clearing heat and removing toxicity, inducing diuresis and reducing swelling, invigorating stomach and the like.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a pharmaceutical composition for preventing gout and a preparation method thereof, which can condition the whole body, can obtain the good effects of gradually clearing damp-heat, gradually dissolving turbid blood stasis and continuously reducing blood uric acid, and further achieve the treatment purposes of eliminating the symptoms of red swelling and hot pain of external joints, reducing internal uric acid and recovering the functions of internal organs to be normal.
The invention provides a chicory inulin-rich composition, which comprises the following raw materials in parts by weight: 40-100 parts of chicory inulin, 10-30 parts of extracts of the cang and the white atractylodes rhizome respectively, 10-30 parts of an artemisia leaf extract, 30-60 parts of a fried coix seed extract, 5-15 parts of an amur corktree bark extract, 20-40 parts of a glabrous greenbrier rhizome extract, 20-40 parts of a clematis root extract, 20-40 parts of a plantain herb extract, 20-40 parts of a giant knotweed rhizome extract, 10-20 parts of an alisma rhizome extract, 10-20 parts of a motherwort herb extract, 10-20 parts of a red paeony root extract, 10-20 parts of earthworm protein powder, 10-20 parts of peach kernel powder, 10-20 parts of a lightyellow sophora root extract, 8-15 parts of a cortex lycii radicis extract, 3-8 parts of.
Preferably, the composition comprises the following raw materials in parts by weight: 50-80 parts of chicory inulin, 15-25 parts of extracts of the cang and the white atractylodes rhizome respectively, 15-25 parts of an artemisia leaf extract, 35-50 parts of a fried coix seed extract, 8-12 parts of an amur corktree bark extract, 25-35 parts of a glabrous greenbrier rhizome extract, 25-35 parts of a clematis root extract, 25-35 parts of a plantain herb extract, 25-35 parts of a giant knotweed rhizome extract, 12-18 parts of an alisma rhizome extract, 12-18 parts of a motherwort herb extract, 12-18 parts of a red paeony root extract, 12-18 parts of earthworm protein powder, 12-18 parts of peach kernel powder, 12-19 parts of a lightyellow sophora root extract, 9-13 parts of a cortex lycii radicis extract, 4-7 parts of.
More preferably, the composition comprises the following raw materials in parts by weight: 60 parts of chicory inulin, 20 parts of extracts of the cang and the white atractylodes rhizome respectively, 20 g of an artemisia leaf extract, 50 parts of a fried coix seed extract, 10 parts of an phellodendron bark extract, 30 parts of a glabrous greenbrier rhizome extract, 30 parts of a clematis root extract, 30 parts of a plantain herb extract, 30 parts of a giant knotweed rhizome extract, 15 parts of an alisma rhizome extract, 15 parts of a motherwort herb extract, 15 parts of a red paeony root extract, 15 parts of earthworm protein powder, 15 parts of peach kernel powder, 15 parts of a sophora flavescens extract, 12 parts of a cortex lycii radicis extract, 6 parts of.
Preferably, the chicory inulin is prepared by a process comprising the following steps:
(1) pulverizing herba Cichorii, mixing with water, heating, reflux extracting, and filtering to obtain primary extractive solution and primary residue;
(2) mixing the primary filter residue obtained in the step (1) with ethanol, heating, refluxing and extracting, and filtering to obtain a secondary extracting solution and secondary filter residue;
(3) and (4) combining the primary extracting solution and the secondary extracting solution, and concentrating and drying the obtained combined solution to obtain the chicory inulin.
Preferably, in step (1), the pulverization is carried out to a particle size of 80 to 120 mesh.
Preferably, in the step (1), the weight ratio of the chicory to the water is 1-3: 4-8; the temperature of the heating reflux is 85-95 ℃, and the time of the heating reflux is 1-3 h.
Preferably, in the step (2), the weight ratio of the primary filter residue to the ethanol is 1-3: 3-5; the heating reflux temperature is 75-85 ℃, and the heating reflux time is 1-3 h.
Preferably, in step (3), the concentration is 10-30% of the original volume.
Preferably, the rotation speed of the mixing is 300-600r/min, and the mixing time is 30-50 min.
The extracts related to the above components can be obtained by extracting by conventional methods in the field or by commercially obtaining.
In a second aspect, the present invention provides a process for the preparation of the above chicory inulin-rich composition, which process comprises: the components are mixed evenly.
In a third aspect, the invention provides a preparation for preventing gout, which is prepared by further processing the chicory inulin-rich composition, and the preparation can be powder, tablets, granules or pills.
The invention has the beneficial effects that:
(1) gout is caused by downward flow of damp-heat, internal stasis, obstruction of channels and collaterals by damp-heat evil, and blockage of channels and collaterals, which affect qi and blood circulation, malnutrition of muscles and bones, blockage of channels and collaterals, and pain caused by obstruction, so that joint pain is severe and activity is limited. Therefore, the invention takes the treatment principles of clearing heat and eliminating dampness, removing stasis and removing obstruction in channels to relieve pain, and uses the atractylodes rhizome, the atractylodes macrocephala koidz and the fried coix seed to remove dampness and strengthen the spleen, dispel wind and remove dampness; rhizoma Smilacis Glabrae, herba plantaginis, and rhizoma Polygoni Cuspidati for removing toxic substance, eliminating dampness, and easing joint movement; the clematis root has the effects of dispelling wind and removing dampness, and dredging collaterals and relieving pain; phellodendron bark, cortex Phellodendri clears heat and dampness, detoxifies; radix Paeoniae Rubra has effects in dispelling blood stasis, relieving pain, clearing away heat, and cooling blood; earthworm protein can remove blood stasis and dredge collaterals; the composition has the effects of clearing heat and removing toxicity, promoting diuresis and removing turbidity by combining with the Indian iphigenia bulb and the peach kernel. The composition of the invention can eliminate the symptoms of swelling and hot pain of external joints, reduce internal uric acid, restore the functions of internal organs to be normal and relieve the pain of muscles, bones and joints.
(3) The preparation method of the composition only needs to uniformly mix all the raw materials, is simple and easy to control in operation, and is beneficial to large-scale production.
Additional features and advantages of the invention will be set forth in the detailed description which follows.
Detailed Description
Preferred embodiments of the present invention will be described in more detail below. While the following describes preferred embodiments of the present invention, it should be understood that the present invention may be embodied in various forms and should not be limited by the embodiments set forth herein.
The present invention is further illustrated by the following examples, which include, but are not limited to, the following examples.
Example 1
The embodiment provides a chicory inulin-rich composition, which comprises the following raw materials in parts by weight: 40 parts of chicory inulin, 10 parts of extracts of the cang and the white atractylodes rhizome respectively, 10 parts of an artemisia leaf extract, 30 parts of a fried coix seed extract, 5 parts of an phellodendron bark extract, 20 parts of a glabrous greenbrier rhizome extract, 20 parts of a clematis root extract, 20 parts of a plantain herb extract, 20 parts of a giant knotweed rhizome extract, 10 parts of an alisma rhizome extract, 10 parts of a motherwort herb extract, 10 parts of a red paeony root extract, 10 parts of earthworm protein powder, 10 parts of peach kernel powder, 10 parts of a sophora flavescens extract, 8 parts of a cortex lycii radicis extract, 3 parts of.
The preparation method of the chicory inulin comprises the following steps:
(1) pulverizing herba Cichorii, mixing with water, heating, reflux extracting, and filtering to obtain primary extractive solution and primary residue;
(2) mixing the primary filter residue obtained in the step (1) with ethanol, heating, refluxing and extracting, and filtering to obtain a secondary extracting solution and secondary filter residue;
(3) mixing the primary extract and the secondary extract, concentrating the obtained mixed solution, and drying to obtain: chicory inulin.
In the step (1), the powder is crushed to a particle size of 80-120 meshes.
In the step (1), the weight ratio of the chicory to the water is 1: 4; the heating reflux temperature is 85 ℃, and the heating reflux time is 1 h.
In the step (2), the weight ratio of the primary filter residue to the ethanol is 1: 3; the heating reflux temperature is 75 ℃, and the heating reflux time is 1 h.
In the step (3), the concentration is 10% of the original volume.
The rotating speed of the mixing is 300r/min, and the mixing time is 30 min.
After mixing well, the composition is further processed into a powder.
Example 2
The embodiment provides a chicory inulin-rich composition, which comprises the following raw materials in parts by weight: 60 parts of chicory inulin, 20 parts of extracts of the cang and the white atractylodes rhizome respectively, 20 g of an artemisia leaf extract, 50 parts of a fried coix seed extract, 10 parts of an phellodendron bark extract, 30 parts of a glabrous greenbrier rhizome extract, 30 parts of a clematis root extract, 30 parts of a plantain herb extract, 30 parts of a giant knotweed rhizome extract, 15 parts of an alisma rhizome extract, 15 parts of a motherwort herb extract, 15 parts of a red paeony root extract, 15 parts of earthworm protein powder, 15 parts of peach kernel powder, 15 parts of a sophora flavescens extract, 12 parts of a cortex lycii radicis extract, 6 parts of.
The preparation method of the chicory inulin comprises the following steps:
(1) pulverizing herba Cichorii, mixing with water, heating, reflux extracting, and filtering to obtain primary extractive solution and primary residue;
(2) mixing the primary filter residue obtained in the step (1) with ethanol, heating, refluxing and extracting, and filtering to obtain a secondary extracting solution and secondary filter residue;
(3) mixing the primary extract and the secondary extract, concentrating the obtained mixed solution, and drying to obtain: chicory inulin.
In the step (1), the powder is crushed to a particle size of 90 meshes.
In the step (1), the weight ratio of the chicory to the water is 1: 5; the heating reflux temperature is 90 ℃, and the heating reflux time is 1.5 h.
In the step (2), the weight ratio of the primary filter residue to the ethanol is 1: 5; the heating reflux temperature is 80 ℃, and the heating reflux time is 1.5 h.
In the step (3), the concentration is 20% of the original volume.
The rotating speed of the mixing is 500r/min, and the mixing time is 40 min.
After mixing well, the composition is further processed into pills.
Example 3
The embodiment provides a composition rich in chicory inulin and capable of preventing gout, which comprises the following raw materials in parts by weight: 100 parts of chicory inulin, 30 parts of extracts of the cang and the white atractylodes rhizome respectively, 30 parts of an artemisia leaf extract, 60 parts of a fried coix seed extract, 15 parts of an phellodendron bark extract, 40 parts of a glabrous greenbrier rhizome extract, 40 parts of a clematis root extract, 40 parts of a plantain herb extract, 40 parts of a giant knotweed rhizome extract, 20 parts of an alisma rhizome extract, 20 parts of a motherwort herb extract, 20 parts of a red paeony root extract, 20 parts of earthworm protein powder, 19 parts of peach kernel powder, 18 parts of a sophora flavescens extract, 15 parts of a cortex lycii radicis extract, 8 parts of.
The preparation method of the chicory inulin comprises the following steps:
(1) pulverizing herba Cichorii, mixing with water, heating, reflux extracting, and filtering to obtain primary extractive solution and primary residue;
(2) mixing the primary filter residue obtained in the step (1) with ethanol, heating, refluxing and extracting, and filtering to obtain a secondary extracting solution and secondary filter residue;
(3) mixing the primary extract and the secondary extract, concentrating the obtained mixed solution, and drying to obtain: chicory inulin.
In the step (1), the powder is crushed to a particle size of 120 meshes.
In the step (1), the weight ratio of the chicory to the water is 3: 8; the heating reflux temperature is 95 ℃, and the heating reflux time is 3 h.
In the step (2), the weight ratio of the primary filter residue to the ethanol is 3: 5; the heating reflux temperature is 75-85 ℃, and the heating reflux time is 1-3 h.
In the step (3), the concentration is 30% of the original volume.
The rotating speed of the mixing is 600r/min, and the mixing time is 50 min.
After mixing to homogeneity, the composition is further processed into tablets.
Test example
1. Test data and methods
80 gout patients are selected as the study objects, and are divided into a control group and an observation group according to different treatment methods adopted by the patients, and all the selected patients are informed and agree to participate in the study. In the control group, 25 women and 25 men in 50 patients have the ages of 41-67 years and the average age (53.4 +/-1.6) years; 25 women and 25 men in 50 patients in an observation group, wherein the patients are 4 l-66 years old and the average age (53.7 +/-1.4) years old; the patient profiles were substantially similar between the two groups (P >0.05) so that statistical comparisons could be made between the groups.
1.2 test methods
The control group is treated by a conventional method, and 50mg of indometacin is selected in the treatment, and the indometacin is taken 3 times in 1 day; 0.5mg of colchicine, which is taken 3 times in 1 day; the administration was continued for 1 week.
The observation group was treated with traditional Chinese medicine and the product of example 2 of the present invention was selected. Both groups are simultaneously fed with diet and life intervention, namely, the patients are guided to reduce the use of purine foods such as eggs and the like, and the patients are kept in bed for rest absolutely.
1.3 Observation index
Observing the condition of the two groups of patients after 3 months of treatment, and evaluating the effect of the two groups of patients; the clinical symptoms of the patient disappear, and the uric acid level in the blood or urine returns to normal and is healed; part of clinical symptoms disappear, part of clinical symptoms are relieved, and the uric acid level in blood or urine is improved but is not normal and is effective; the patients were ineffective if neither clinical symptoms nor uric acid levels improved nor evidence of exacerbation appeared; wherein the sum of the significant efficiency and the effective rate is the total effective rate of the treatment. The mean time to remission was also counted for both groups of patients.
1.4 statistical analysis
The data of the study are processed by SPSS21.0 software, and the counting data are counted by n and are counted by x2Checking, the measured data are expressed as (X + -S) and checked by t, if the obtained P is checked<0.05, it means that the compared data have significant difference and are statistically significant.
2. The effective rate of the two groups of patients is detailed in table 1.
Table 1: comparison of two groups for therapeutic efficacy (%)
| Group of | n | Show effect | Is effective | Invalidation | Total effective rate |
| Observation group | 50 | 29 | 20 | 1 | 49(98％) |
| Control group | 50 | 20 | 19 | 11 | 39(78％) |
| X2 | / | / | / | / | 13.72 |
| P | / | / | / | / | ＜0.05 |
The results show that: the average symptom relieving time of the patients in the observation group is (4.23 +/-1.02) days, which is shorter than the (7.25 +/-1.05) days of the control group, the treatment effective rate of the observation group is 98 percent higher than that of the control group by 78 percent, and the comparison difference between the two groups is obvious (x)2Is 6.35, P<0.05). The composition has good effect on gout, can promote patients to recover in time, and improves the effective rate of clinical treatment.
Having described embodiments of the present invention, the foregoing description is intended to be exemplary, not exhaustive, and not limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments.
Claims (10)
1. A composition rich in chicory inulin is characterized by comprising the following raw materials in parts by weight: 40-100 parts of chicory inulin, 10-30 parts of extracts of the cang and the white atractylodes rhizome respectively, 10-30 parts of an artemisia leaf extract, 30-60 parts of a fried coix seed extract, 5-15 parts of an amur corktree bark extract, 20-40 parts of a glabrous greenbrier rhizome extract, 20-40 parts of a clematis root extract, 20-40 parts of a plantain herb extract, 20-40 parts of a giant knotweed rhizome extract, 10-20 parts of an alisma rhizome extract, 10-20 parts of a motherwort herb extract, 10-20 parts of a red paeony root extract, 10-20 parts of earthworm protein powder, 10-20 parts of peach kernel powder, 10-20 parts of a lightyellow sophora root extract, 8-15 parts of a cortex lycii radicis extract, 3-8 parts of.
2. Chicory inulin-rich composition according to claim 1, wherein the composition comprises the following raw materials in parts by weight: 50-80 parts of chicory inulin, 15-25 parts of extracts of the cang and the white atractylodes rhizome respectively, 15-25 parts of an artemisia leaf extract, 35-50 parts of a fried coix seed extract, 8-12 parts of an amur corktree bark extract, 25-35 parts of a glabrous greenbrier rhizome extract, 25-35 parts of a clematis root extract, 25-35 parts of a plantain herb extract, 25-35 parts of a giant knotweed rhizome extract, 12-18 parts of an alisma rhizome extract, 12-18 parts of a motherwort herb extract, 12-18 parts of a red paeony root extract, 12-18 parts of earthworm protein powder, 12-18 parts of peach kernel powder, 12-19 parts of a lightyellow sophora root extract, 9-13 parts of a cortex lycii radicis extract, 4-7 parts of.
3. Chicory inulin-rich composition according to claim 2, wherein the composition comprises the following raw materials in parts by weight: 60 parts of chicory inulin, 20 parts of extracts of the cang and the white atractylodes rhizome respectively, 20 g of an artemisia leaf extract, 50 parts of a fried coix seed extract, 10 parts of an phellodendron bark extract, 30 parts of a glabrous greenbrier rhizome extract, 30 parts of a clematis root extract, 30 parts of a plantain herb extract, 30 parts of a giant knotweed rhizome extract, 15 parts of an alisma rhizome extract, 15 parts of a motherwort herb extract, 15 parts of a red paeony root extract, 15 parts of earthworm protein powder, 15 parts of peach kernel powder, 15 parts of a sophora flavescens extract, 12 parts of a cortex lycii radicis extract, 6 parts of.
4. Chicory inulin-enriched composition according to any one of claims 1-3, wherein the chicory inulin is prepared by a process comprising the following steps:
(1) pulverizing herba Cichorii, mixing with water, heating, reflux extracting, and filtering to obtain primary extractive solution and primary residue;
(2) mixing the primary filter residue obtained in the step (1) with ethanol, heating, refluxing and extracting, and filtering to obtain a secondary extracting solution and secondary filter residue;
(3) and (4) combining the primary extracting solution and the secondary extracting solution, and concentrating and drying the obtained combined solution to obtain the chicory inulin.
5. Chicory inulin-rich composition according to claim 4, wherein in step (1) the grinding is to a particle size of 80-120 mesh;
the weight ratio of the chicory to the water is 1-3: 4-8;
the temperature of the heating reflux is 85-95 ℃, and the time of the heating reflux is 1-3 h.
6. Chicory inulin-rich composition according to claim 4, wherein in step (2) the weight ratio of the primary filter residue to ethanol is 1-3: 3-5;
the heating reflux temperature is 75-85 ℃, and the heating reflux time is 1-3 h.
7. Chicory inulin-rich composition according to claim 4, wherein in step (3) the concentration is to 10-30% of the original volume.
8. Chicory inulin-rich composition according to claim 4, wherein the mixing is carried out at a rotational speed of 300-600r/min for a time of 30-50 min.
9. A process for the preparation of a chicory inulin-rich composition as claimed in any one of claims 1-3, which process comprises: the components are mixed evenly.
10. A preparation for preventing gout is prepared by further processing the chicory inulin-rich composition of any one of 1-3, and is powder, tablets, granules or pills.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911338991.3A CN111068043B (en) | 2019-12-23 | 2019-12-23 | Composition rich in chicory and inulin, preparation method thereof and preparation for preventing gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911338991.3A CN111068043B (en) | 2019-12-23 | 2019-12-23 | Composition rich in chicory and inulin, preparation method thereof and preparation for preventing gout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111068043A true CN111068043A (en) | 2020-04-28 |
| CN111068043B CN111068043B (en) | 2022-07-12 |
Family
ID=70316860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911338991.3A Active CN111068043B (en) | 2019-12-23 | 2019-12-23 | Composition rich in chicory and inulin, preparation method thereof and preparation for preventing gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111068043B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115399482A (en) * | 2022-01-29 | 2022-11-29 | 中科国健(天津)生物工程有限公司 | Earthworm protein nutrition powder and nutrition paste for relieving gout and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140212519A1 (en) * | 2013-01-30 | 2014-07-31 | Infinitus (China) Company Ltd. | Chinese herbal medicine composition having a function of reducing uric acid |
| CN105056020A (en) * | 2015-07-29 | 2015-11-18 | 郑州中医骨伤病医院 | Lingxian pill for treating gout and preparation method of pill |
| US20170014467A1 (en) * | 2015-07-14 | 2017-01-19 | Infinitus (China) Company Ltd. | Composition and the use thereof |
| WO2017101151A1 (en) * | 2015-12-14 | 2017-06-22 | 华坚 | Gout treating traditional chinese medicine composition and preparation method therefor |
-
2019
- 2019-12-23 CN CN201911338991.3A patent/CN111068043B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140212519A1 (en) * | 2013-01-30 | 2014-07-31 | Infinitus (China) Company Ltd. | Chinese herbal medicine composition having a function of reducing uric acid |
| US20170014467A1 (en) * | 2015-07-14 | 2017-01-19 | Infinitus (China) Company Ltd. | Composition and the use thereof |
| CN105056020A (en) * | 2015-07-29 | 2015-11-18 | 郑州中医骨伤病医院 | Lingxian pill for treating gout and preparation method of pill |
| WO2017101151A1 (en) * | 2015-12-14 | 2017-06-22 | 华坚 | Gout treating traditional chinese medicine composition and preparation method therefor |
Non-Patent Citations (1)
| Title |
|---|
| 张爱国等: "清络祛风汤合五虫祛风散治疗痛风性关节炎97例临床观察", 《广州中医药大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115399482A (en) * | 2022-01-29 | 2022-11-29 | 中科国健(天津)生物工程有限公司 | Earthworm protein nutrition powder and nutrition paste for relieving gout and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111068043B (en) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524494A (en) | Drug for treating gout | |
| CN111068043B (en) | Composition rich in chicory and inulin, preparation method thereof and preparation for preventing gout | |
| US20190038706A1 (en) | Medicament for use in treating gout | |
| CN109820943B (en) | Zhuang medicine preparation for treating gout and preparation method thereof | |
| CN103432485B (en) | Chinese medicinal preparation for treating urinary calculus and preparation method | |
| CN102018903B (en) | Pure traditional Chinese medicine preparation for treating glomerular diseases and preparation method thereof | |
| CN103169900B (en) | Chinese herba preparation for treating gout | |
| CN1259961C (en) | Medicination for curing kidney disease and preparation method | |
| CN107812093B (en) | Traditional Chinese medicine composition for treating gouty nephropathy and gouty arthritis and preparation method thereof | |
| CN105963597A (en) | Traditional Chinese medicine for treating oral ulcer | |
| CN105770487A (en) | Traditional Chinese medicine composition for treating cerebral infarction and cerebral hemorrhage sequelae and preparation method thereof | |
| CN110755489A (en) | Traditional Chinese medicine for treating gout and preparation method thereof | |
| CN104000938A (en) | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof | |
| CN115040565B (en) | Enema traditional Chinese medicine for reducing creatinine and preparation method and application thereof | |
| CN114470144B (en) | Prostate eliminating soup for inhibiting prostate fibrosis and preparation method thereof | |
| CN105878198A (en) | Pharmaceutical composition containing berberine hydrochloride tablets and preparation process thereof | |
| CN112826888B (en) | Traditional Chinese medicine composition for gout and preparation method and application thereof | |
| CN109758505B (en) | Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof | |
| CN117379505A (en) | Traditional Chinese medicine composition for treating chronic kidney disease | |
| CN105012808A (en) | Medicinal preparation for treating gout | |
| CN115645493A (en) | Traditional Chinese medicine preparation for treating chronic kidney disease in stage 3 and preparation method thereof | |
| CN105194482A (en) | Medicine preparation for treating chronic nephrosis | |
| CN116747280A (en) | Traditional Chinese medicine fermentation preparation for preventing and treating gout and preparation method and application thereof | |
| CN116688062A (en) | Composition capable of reducing blood uric acid concentration and preparation method thereof | |
| CN113332367A (en) | Wild pineapple extract and application thereof in preparation of medicine for treating hyperuricemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240103 Address after: No. 101, Quanli Second Road, Wuhan Economic and Technological Development Zone, Wuhan City, Hubei Province 430058 Economic and Technological Development Zone 2045 Innovation Valley D217 Patentee after: WUHAN WALKSUN BIOTECHNOLOGY Co.,Ltd. Address before: 430023 No. 68 Xuefu South Road, Changqing Garden, Hankou, Wuhan, Hubei. Patentee before: WUHAN POLYTECHNIC University |
|
| TR01 | Transfer of patent right |